Participants 121 255 5
OBJECTIVE Autosomal dominant polycystic kidney disease (ADPKD) is progressive, resulting in end-stage kidney failure in most patients.
Participants 404 595 4
MATERIAL AND METHODS This randomized open-label clinical trial was conducted to assess the effect of pravastatin 20 mg on kidney function and urinary protein excretion in patients with ADPKD.
Participants 596 713 5
Sixty patients were initially recruited but 49 of these received either pravastatin 20 mg or no treatment for 2 years
